Press Release

Integra Lifesciences Corporation, Organogenesis, Inc., Zimmer Biomet, Inc., and B. Braun Melsungen AG is Dominating the Market for Global Skin Graft Market in 2017

Global Skin Graft Market is expected to reach USD 1,192.36 million by 2025 from USD 683.72 million in 2017, at a CAGR of 7.3% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Global Skin Graft MarketAccess Full Report:

The global skin graft market highly concentrated to a few big players and rest to local players who cater to domestic markets only. Integra Lifesciences Corporation dominated the skin graft market accounting for a highest market share in 2017, followed by Organogenesis, Inc., Zimmer Biomet, Inc., B. Braun Melsungen AG. Other players in this market include are Nouvag AG, DE Soutter Medical Limited, Surtex Instruments Limited, Exsurco Medical, Inc. among others.

Integra Lifesciences Corporation:

Integra Lifesciences Corporation was founded in 1989, and is headquartered at New Jersey; U.S. Integra Lifesciences Corporation focuses on manufacturing of devices used in neurosurgery, orthopaedic extremity surgery, and reconstructive and general surgery. Integra Life Sciences Corporation operates its business through two business segments: specialty surgical solutions and orthopaedics and tissue technologies. The specialty surgical solutions segment provides specialty surgical instrumentation for specialties, products used in the neurosurgery operating suite and in critical care unit. They offer skin grafts products including different dermatomes, few surgical accessories for skin graft procedure and dermal regeneration template.

The company's operations span across North & South America, Europe, Australia, China, India, Japan, Korea and Taiwan& South East Asia. Some of its subsidiaries include Ascension Orthopedics, Inc. (Delaware), Ascension Orthopedics, Ltd. (U.K.), Integra LS (Benelux) NV (Belgium), Integra ME GmbH (Germany), Integra Neurosciences Pty Ltd. (New Zealand), IsoTis International SA (Switzerland), IsoTisOrtho Biologics, Inc. (Washington), Precision Dental International, Inc. (California), among others.

Some of the recent developments of the company:

  • In May 2017, Integra LifeSciences Holdings Corporation launched Integra Dermal Regeneration Template Single Layer (IDRT) in Europe. It is a simple single step procedure. IDRT is used in the repair of dermal defects. The launch of this technology in Europe will increase the customer base and company’s growth in the region.
  • In January 2017, Integra Derma, Inc., a subsidiary of Integra LifeSciences Holdings Corporation acquired Derma Sciences, Inc. Derma Sciences provides various products in wound closure category, which will enhance the product portfolio of Integra.
  • In April 2016, In April, Integra LifeSciences Holding Corporation entered into an agreement with AlloSource. In this agreement, Integra will provide bone, cellular, skin and soft-tissue allografts for surgical procedures and wound care treatment. This agreement has augmented the surgical wound care products of the company in the market.


Organogenesis Inc. was established in 1985, and is located at Massachusetts, U.S. Organogenesis Inc. focuses on manufacturing and sales of products. These products are used in the surgical, advanced wound care, and sports medicine. Organogenesis Inc. was originally founded as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT). The company operates its business through the various products such Affinity, NuShield, Apligraf, Dermagraft, ReNu, NuCel, and PuraPly, which are used in wound care, sports medicine field. The skin graft products are available under the advanced wound care segment such as Dermagraft. The company's operations span across North America, and Europe. The subsidiaries of the company comprises of the NuTech Medical (U.S.).

Some of the recent developments of the company:

  • In March 2017, Organogenesis Inc. acquired NuTech Medical. The NuTech Medical provides products for the wound care and surgical biologics markets. This acquisition will enhance the product portfolio of the Organogenesis in regenerative and wound care market.
  • In January 2014, Organogenesis Inc. purchased the rights of Shire plc. Dermagraft, which is used as a dermal substitute of human fibroblast for the treatment of diabities foot ulcers. This acquisition of the product will increase the company’s portfolio in the regenerative medicine field.


Zimmer Biomet was established in the year of 1927, and it is headquartered in Warsaw, Indiana, U.S. Zimmer Biomet is engaged in the manufacturing and commercialization of the orthopedic reconstructive products, biologics, sports medicine, spine and CMF products, extremities and trauma products. It also delivers office based technologies, dental implants; and related surgical products. The company majorly operates its business through six different product categories, knees, hips, spine & CMF, SET, dental, and other. The knee product category offers products which include early intervention and joint preservation. These products provide the preservation to the joint by repairing or regenerating the injured tissues and by the treatment of osteoarthritis. The skin graft products are available in the knee product category.

On August 6, 2001, the company spun off from their former parent and became an independent public company. On June 24, 2015, Zimmer acquired LVB Acquisition, Inc., the parent company of Biomet, Inc., and LVB and Biomet became wholly-owned subsidiaries of Zimmer. After the merger, Zimmer changed its name from Zimmer Holdings, Inc., to Zimmer Biomet Holdings, Inc. The company’s its presence across North America, EMEA and Asia-Pacific. Some of the subsidiaries of the company include Zimmer US, Inc. (U.S.), Zimmer Production, Inc. (U.S.), Zimmer Germany GmbH (Germany), Zimmer India Pvt. Ltd. (India), Zimmer CEP USA Holding Co. (U.S.) Biomet UK Ltd. (UK) and others.

Few of the recent developments of the company:

  • In June 2015, Zimmer Holdings, Inc. acquired Biomet. The company changed its name after the acquisition to Zimmer Biomet Holdings, Inc. This acquisition helped in expanding the portfolio of the company, and will provide better and advanced treatment to patients. The products of the Biomet Company will be sold by Zimmer Biomet Holdings, Inc.
  • In November 2011, Zimmer Holdings, Inc. established its research and development center in Beijing, China. The center focuses on the technologically advanced research and development programs Asia. This development has increased the company’s position in China, which is one of the highest growing economies in Asia.


B.Braun Melsungen AG was founded in 1839. It is situated at Melsungen in Germany. The company is involved in the manufacturing of the medical products and in the marketing of the healthcare solutions. The operating business segment includes hospital care, Aesculap, B.Braun Avitum, OPM, and others. The company offers a wide range of products for intensive care units, anesthesia, emergency care, extra corporeal, blood treatments and surgical core procedures for hospitals, surgical centers and other private medical institutes. The Aesculap business segment provides variety of products for the minimally invasive surgeries, surgical sutures, implants which include orthopaedics, neurosurgery and spinal surgery, sterile container, storage, motor and navigation systems as well as products for cardiology. The skin graft products are offered under the skin graft mesher product category of the Aesculap business segment of the company.

The company has its offices and facilities in over 50 countries. B.Braun Melsungen AG and its subsidiaries currently employ more than 54000 people in more than 60 countries. It has several subsidiaries such as Aesculap (U.S.), B. Braun Medical Inc. (U.S.), B. Braun Medical (India) Pvt. Ltd. (India), B. Braun of America, Inc. (U.S.), Saxonia Medical Gmbh (Germany), and others.

Some of the recent developments of the company:

  • In December, B. Braun started a new subsidiary in Zambia. The subsidiary offers products for the treatment to the local population. This establishment has increased the customer base of the company in Africa.

Client Testimonials